GIP is increasingly recognized as a "buffer" for metabolic health, enhancing insulin secretion in a glucose-dependent manner while potentially mitigating the nausea often associated with GLP-1 receptor activation
Wang G, Su Z, Li H, Xiao L, Li C, Lian G
Lilly, for instance, already markets tirzepatide and is also banking on orforglipron, a once-daily small-molecule GLP-1 agonist that can be taken as a pill
A parabrachial-hypothalamic cholecystokinin neurocircuit controls counterregulatory responses to hypoglycemia
Treatment of adult obstructive sleep apnea with positive airway pressure: an American academy of sleep medicine systematic review, meta-analysis, and GRADE assessment
Which I am still doing now